Skip to main content
Erschienen in: International Journal of Hematology 5/2021

30.07.2021 | Case Report

Mycobacterial lymphadenitis without granuloma formation in a patient with anti-interferon-gamma antibodies

Erschienen in: International Journal of Hematology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

A previously healthy 49-year-old Japanese woman presented with cervical lymph node swelling and tenderness. Lymph node biopsy revealed reactive lymphadenitis without granulomas. No malignant cells were found, and no acid-fast positive bacilli were identified by Ziehl–Neelsen staining. She was treated unsuccessfully with various antibiotics, and it was very challenging to reach a diagnosis. 18F-Fluorodeoxyglucose (18F-FDG) uptake in bones was evaluated using positron emission tomography-computed tomography (PET-CT), and disseminated mycobacterial infection was suspected. The interferon-gamma (IFN-γ) release assays QuantiFERON (QFT) and T-SPOT were used to diagnose tuberculosis infection. On testing, a difference in mitogen response was found between these assays. The response was low for QFT but adequate for T-SPOT, suggesting the presence of anti-IFN-γ antibodies. This difference depended on whether the patient’s plasma (including anti-IFN-γ antibodies) was used within the assay system. Mycobacterium abscessus was isolated from lymph node cultures, and plasma anti-IFN-γ antibodies were confirmed. The patient was diagnosed with disseminated M. abscessus infection with underlying adult-onset immunodeficiency caused by anti-IFN-γ antibodies. Granulomas are a pathological hallmark of mycobacterial infection, but may not fully form in immunodeficient patients. Clinicians should be aware of the possibility of mycobacterial infection without granuloma formation due to anti-IFN-γ antibodies.
Literatur
1.
Zurück zum Zitat Abdissa K, Tadesse M, Abdella K, Bekele A, Bezabih M, Abebe G. Diagnostic performance of fluorescent light-emitting diode microscopy for tuberculous lymphadenitis in a high-burden setting. Trop Med Int Health. 2015;20:1543–8.CrossRef Abdissa K, Tadesse M, Abdella K, Bekele A, Bezabih M, Abebe G. Diagnostic performance of fluorescent light-emitting diode microscopy for tuberculous lymphadenitis in a high-burden setting. Trop Med Int Health. 2015;20:1543–8.CrossRef
2.
Zurück zum Zitat Tadesse M, Abebe G, Abdissa K, Bekele A, Bezabih M, Apers L, et al. Concentration of lymph node aspirate improves the sensitivity of acid fast smear microscopy for the diagnosis of tuberculous lymphadenitis in Jimma, southwest Ethiopia. PLoS ONE. 2014;9:e106726.CrossRef Tadesse M, Abebe G, Abdissa K, Bekele A, Bezabih M, Apers L, et al. Concentration of lymph node aspirate improves the sensitivity of acid fast smear microscopy for the diagnosis of tuberculous lymphadenitis in Jimma, southwest Ethiopia. PLoS ONE. 2014;9:e106726.CrossRef
3.
Zurück zum Zitat North RJ, Izzo AA. Granuloma formation in severe combined immunodeficient (SCID) mice in response to progressive BCG infection. Tendency not to form granulomas in the lung is associated with faster bacterial growth in this organ. Am J Pathol. 1993;142:1959–66.PubMedPubMedCentral North RJ, Izzo AA. Granuloma formation in severe combined immunodeficient (SCID) mice in response to progressive BCG infection. Tendency not to form granulomas in the lung is associated with faster bacterial growth in this organ. Am J Pathol. 1993;142:1959–66.PubMedPubMedCentral
4.
Zurück zum Zitat Aoki A, Sakagami T, Yoshizawa K, Shima K, Toyama M, Tanabe Y, et al. Clinical significance of interferon-gamma neutralizing autoantibodies against disseminated nontuberculous mycobacterial disease. Clin Infect Dis. 2018;66:1239–45.CrossRef Aoki A, Sakagami T, Yoshizawa K, Shima K, Toyama M, Tanabe Y, et al. Clinical significance of interferon-gamma neutralizing autoantibodies against disseminated nontuberculous mycobacterial disease. Clin Infect Dis. 2018;66:1239–45.CrossRef
5.
Zurück zum Zitat Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367:725–34.CrossRef Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367:725–34.CrossRef
6.
Zurück zum Zitat Dioguardi P, Gaddam SR, Zhuang H, Torigian DA, Alavi A. FDG PET assessment of osteomyelitis: a review. PET Clin. 2012;7:161–79.CrossRef Dioguardi P, Gaddam SR, Zhuang H, Torigian DA, Alavi A. FDG PET assessment of osteomyelitis: a review. PET Clin. 2012;7:161–79.CrossRef
7.
Zurück zum Zitat Gamaletsou MN, Rammaert B, Bueno MA, Moriyama B, Sipsas NV, Kontoyiannis DP, et al. Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome. J Infect. 2014;68:478–93.CrossRef Gamaletsou MN, Rammaert B, Bueno MA, Moriyama B, Sipsas NV, Kontoyiannis DP, et al. Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome. J Infect. 2014;68:478–93.CrossRef
8.
Zurück zum Zitat Petitjean G, Fluckiger U, Scharen S, Laifer G. Vertebral osteomyelitis caused by non-tuberculous mycobacteria. Clin Microbiol Infect. 2004;10:951–3.CrossRef Petitjean G, Fluckiger U, Scharen S, Laifer G. Vertebral osteomyelitis caused by non-tuberculous mycobacteria. Clin Microbiol Infect. 2004;10:951–3.CrossRef
9.
Zurück zum Zitat Carek PJ, Dickerson LM, Sack JL. Diagnosis and management of osteomyelitis. Am Fam Physician. 2001;63:2413–20.PubMed Carek PJ, Dickerson LM, Sack JL. Diagnosis and management of osteomyelitis. Am Fam Physician. 2001;63:2413–20.PubMed
10.
Zurück zum Zitat Vohra R, Kang HS, Dogra S, Saggar RR, Sharma R. Tuberculous osteomyelitis. J Bone Joint Surg Br. 1997;79:562–6.CrossRef Vohra R, Kang HS, Dogra S, Saggar RR, Sharma R. Tuberculous osteomyelitis. J Bone Joint Surg Br. 1997;79:562–6.CrossRef
11.
Zurück zum Zitat Staines-Boone AT, Deswarte C, Venegas Montoya E, Sanchez-Sanchez LM, Garcia Campos JA, Muniz-Ronquillo T, et al. Multifocal recurrent osteomyelitis and hemophagocytic lymphohistiocytosis in a boy with partial dominant IFN-gammaR1 deficiency: case report and review of the literature. Front Pediatr. 2017;5:75.CrossRef Staines-Boone AT, Deswarte C, Venegas Montoya E, Sanchez-Sanchez LM, Garcia Campos JA, Muniz-Ronquillo T, et al. Multifocal recurrent osteomyelitis and hemophagocytic lymphohistiocytosis in a boy with partial dominant IFN-gammaR1 deficiency: case report and review of the literature. Front Pediatr. 2017;5:75.CrossRef
12.
Zurück zum Zitat Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. Semin Immunol. 2014;26:454–70.CrossRef Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. Semin Immunol. 2014;26:454–70.CrossRef
13.
Zurück zum Zitat Shima K, Sakagami T, Tanabe Y, Aoki N, Moro H, Koya T, et al. Novel assay to detect increased level of neutralizing anti-interferon gamma autoantibodies in non-tuberculous mycobacterial patients. J Infect Chemother. 2014;20:52–6.CrossRef Shima K, Sakagami T, Tanabe Y, Aoki N, Moro H, Koya T, et al. Novel assay to detect increased level of neutralizing anti-interferon gamma autoantibodies in non-tuberculous mycobacterial patients. J Infect Chemother. 2014;20:52–6.CrossRef
14.
Zurück zum Zitat Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian J Med Res. 2020;152:185–226.CrossRef Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian J Med Res. 2020;152:185–226.CrossRef
15.
Zurück zum Zitat van de Vosse E, van Dissel JT, Ottenhoff TH. Genetic deficiencies of innate immune signalling in human infectious disease. Lancet Infect Dis. 2009;9:688–98.CrossRef van de Vosse E, van Dissel JT, Ottenhoff TH. Genetic deficiencies of innate immune signalling in human infectious disease. Lancet Infect Dis. 2009;9:688–98.CrossRef
16.
Zurück zum Zitat Filipe-Santos O, Bustamante J, Chapgier A, Vogt G, de Beaucoudrey L, Feinberg J, et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol. 2006;18:347–61.CrossRef Filipe-Santos O, Bustamante J, Chapgier A, Vogt G, de Beaucoudrey L, Feinberg J, et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol. 2006;18:347–61.CrossRef
17.
Zurück zum Zitat Kampmann B, Hemingway C, Stephens A, Davidson R, Goodsall A, Anderson S, et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest. 2005;115:2480–8.CrossRef Kampmann B, Hemingway C, Stephens A, Davidson R, Goodsall A, Anderson S, et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest. 2005;115:2480–8.CrossRef
18.
Zurück zum Zitat Angkasekwinai N, Suputtamongkol Y, Phoompoung P, Pithukpakorn M, Wongswat E, Umrod P, et al. Clinical outcome and laboratory markers for predicting disease activity in patients with disseminated opportunistic infections associated with anti-interferon-gamma autoantibodies. PLoS ONE. 2019;14:e0215581.CrossRef Angkasekwinai N, Suputtamongkol Y, Phoompoung P, Pithukpakorn M, Wongswat E, Umrod P, et al. Clinical outcome and laboratory markers for predicting disease activity in patients with disseminated opportunistic infections associated with anti-interferon-gamma autoantibodies. PLoS ONE. 2019;14:e0215581.CrossRef
19.
Zurück zum Zitat Nishimura T, Fujita-Suzuki Y, Yonemaru M, Ohkusu K, Sakagami T, Carpenter SM, et al. Recurrence of disseminated Mycobacterium avium complex disease in a patient with anti-gamma interferon autoantibodies by reinfection. J Clin Microbiol. 2015;53:1436–8.CrossRef Nishimura T, Fujita-Suzuki Y, Yonemaru M, Ohkusu K, Sakagami T, Carpenter SM, et al. Recurrence of disseminated Mycobacterium avium complex disease in a patient with anti-gamma interferon autoantibodies by reinfection. J Clin Microbiol. 2015;53:1436–8.CrossRef
20.
Zurück zum Zitat Hase I, Morimoto K, Sakagami T, Ishii Y, van Ingen J. Patient ethnicity and causative species determine the manifestations of anti-interferon-gamma autoantibody-associated nontuberculous mycobacterial disease: a review. Diagn Microbiol Infect Dis. 2017;88:308–15.CrossRef Hase I, Morimoto K, Sakagami T, Ishii Y, van Ingen J. Patient ethnicity and causative species determine the manifestations of anti-interferon-gamma autoantibody-associated nontuberculous mycobacterial disease: a review. Diagn Microbiol Infect Dis. 2017;88:308–15.CrossRef
21.
Zurück zum Zitat Kaneshiro K, Takatsuki K, Kanamori K. A healthy adult with disseminated nontuberculous mycobacterial infection with multiple bone lesions. Kekkaku. 2015;90:457–61.PubMed Kaneshiro K, Takatsuki K, Kanamori K. A healthy adult with disseminated nontuberculous mycobacterial infection with multiple bone lesions. Kekkaku. 2015;90:457–61.PubMed
22.
Zurück zum Zitat Kalayjian RC, Toossi Z, Tomashefski JF Jr, Carey JT, Ross JA, Tomford JW, et al. Pulmonary disease due to infection by Mycobacterium avium complex in patients with AIDS. Clin Infect Dis. 1995;20:1186–94.CrossRef Kalayjian RC, Toossi Z, Tomashefski JF Jr, Carey JT, Ross JA, Tomford JW, et al. Pulmonary disease due to infection by Mycobacterium avium complex in patients with AIDS. Clin Infect Dis. 1995;20:1186–94.CrossRef
23.
Zurück zum Zitat Kakugawa T, Mukae H, Kajiki S, Tanaka A, Yamayoshi T, Inoue M, et al. Mycobacterium avium pleuritis in a non-immunocompromised patient. Intern Med. 2008;47:1727–31.CrossRef Kakugawa T, Mukae H, Kajiki S, Tanaka A, Yamayoshi T, Inoue M, et al. Mycobacterium avium pleuritis in a non-immunocompromised patient. Intern Med. 2008;47:1727–31.CrossRef
24.
Zurück zum Zitat Wu UI, Chuang YC, Sheng WH, Sun HY, Jhong YT, Wang JY, et al. Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-gamma autoantibodies in patients with disseminated nontuberculous mycobacterial infection. Clin Microbiol Infect. 2018;24:159–65.CrossRef Wu UI, Chuang YC, Sheng WH, Sun HY, Jhong YT, Wang JY, et al. Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-gamma autoantibodies in patients with disseminated nontuberculous mycobacterial infection. Clin Microbiol Infect. 2018;24:159–65.CrossRef
25.
Zurück zum Zitat Suarez I, Lehmann C, Gruell H, Graeb J, Kochanek M, Fatkenheuer G, et al. Repurposing QuantiFERON for detection of neutralizing interferon-gamma autoantibodies in patients with nontuberculous mycobacterial infections. Clin Infect Dis. 2017;65:518–21.CrossRef Suarez I, Lehmann C, Gruell H, Graeb J, Kochanek M, Fatkenheuer G, et al. Repurposing QuantiFERON for detection of neutralizing interferon-gamma autoantibodies in patients with nontuberculous mycobacterial infections. Clin Infect Dis. 2017;65:518–21.CrossRef
26.
Zurück zum Zitat Takasaki J, Manabe T, Morino E, Muto Y, Hashimoto M, Iikura M, et al. Sensitivity and specificity of QuantiFERON-TB Gold Plus compared with QuantiFERON-TB Gold In-Tube and T-SPOT.TB on active tuberculosis in Japan. J Infect Chemother. 2018;24:188–92.CrossRef Takasaki J, Manabe T, Morino E, Muto Y, Hashimoto M, Iikura M, et al. Sensitivity and specificity of QuantiFERON-TB Gold Plus compared with QuantiFERON-TB Gold In-Tube and T-SPOT.TB on active tuberculosis in Japan. J Infect Chemother. 2018;24:188–92.CrossRef
28.
Zurück zum Zitat Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356:1099–104.CrossRef Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356:1099–104.CrossRef
29.
Zurück zum Zitat Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, et al. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection—United States, 2010. MMWR Recomm Rep. 2010;59:1–25.PubMed Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, et al. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection—United States, 2010. MMWR Recomm Rep. 2010;59:1–25.PubMed
30.
Zurück zum Zitat Arend SM, Thijsen SF, Leyten EM, Bouwman JJ, Franken WP, Koster BF, et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med. 2007;175:618–27.CrossRef Arend SM, Thijsen SF, Leyten EM, Bouwman JJ, Franken WP, Koster BF, et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med. 2007;175:618–27.CrossRef
31.
Zurück zum Zitat Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med. 2005;172:631–5.CrossRef Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med. 2005;172:631–5.CrossRef
Metadaten
Titel
Mycobacterial lymphadenitis without granuloma formation in a patient with anti-interferon-gamma antibodies
Publikationsdatum
30.07.2021
Erschienen in
International Journal of Hematology / Ausgabe 5/2021
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-021-03199-3

Weitere Artikel der Ausgabe 5/2021

International Journal of Hematology 5/2021 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.